Lilly breaks ground on $3.5B Pennsylvania injectables plant whose first named drug is still in trials

On Nov. 12, Eli Lilly broke ground on a $3.5 billion manufacturing facility in Fogelsville, in Pennsylvania's Lehigh Valley. The plant will produce injectable medicines, retatrutide among them. That molecule remains investigational, so it may not legally be marketed or sold for use in humans. Retatrutide is a once-weekly triple hormone receptor agonist: one molecule that activates the body's GIP, GLP-1 and glucagon receptors. Lilly is testing it in several Phase 3 clinical trials. The company expects the site to be operational by 2031.

Lilly broke ground on November 12, 2026, on a plant expected to be operational by 2031 that will make injectable medicines, including retatrutide, an investigational molecule that cannot be legally sold or marketed for human use. For anyone who plans manufacturing capacity, that gap between shovel and output is the useful part of the announcement. It shows how far ahead of a clinical result an injectables maker has to commit, and what Lilly thinks a new plant needs inside it.

Pharma Manufacturing reported that the site will manufacture injectable medicines and is expected to create 850 jobs. Lilly CEO Dave Ricks said the facility will make the company's next generation of obesity medicines for people at home and around the world, adding, "this will be an export site for Lilly." The Morning Call called it the largest single project in Lehigh Valley history.

Ordered before the trials finish

Lehigh Valley is part of a plan Lilly laid out in February 2025. Pharma Manufacturing reported then that Lilly committed $27 billion to four new U.S. sites: three for active pharmaceutical ingredients and a fourth to extend its parenteral network for future injectable therapies. Lilly said at the time that the new facilities would begin making medicines within five years. The Fogelsville facility is part of that $27 billion investment.

In its annual report, Lilly acknowledged there were "periods of 2024" when demand for its incretin medicines exceeded production, and said tirzepatide supply then exceeded demand in the U.S. That history suggests why the company would want more capacity. A company that has seen demand exceed production could have reason to add capacity for the next generation while that generation is still in trials.

The bet is broader than one molecule, though. Lilly's release says the site will make injectable medicines including retatrutide, and Ricks described retatrutide as one of several next-generation obesity and diabetes medicines in development. That suggests the plant is sized for a class of injectable products. If one Phase 3 readout disappoints, an injectable-and-device site still has other work to do. That makes the 2031 date less risky than the headline makes it sound.

For supply-chain planners at other drugmakers and contract manufacturers, the timeline itself is a reference point. Counting from this groundbreaking to the 2031 target, a greenfield injectable plant at this scale takes roughly four to five years from first dirt to production. Capacity for products in late-stage trials needs to be in capital plans before the data comes in, not after.

Automation from receiving dock to warehouse

According to Lilly's announcement, the site will rely on AI, machine learning, advanced data analytics and digitally integrated systems so that work is done right the first time, with digital automation built in at every stage. Roberto Vázquez Sanabria, who heads the Lilly Lehigh Valley site, described the goal simply: a fully automated process running from the receipt of materials through the warehouse.

The quality numbers show why that matters. At the ceremony, Ricks said every production run passes through more than 5,000 documented steps and every pen is imaged and inspected more than 70 times before it ships. Lilly's own release gives the same figures to Edgardo Hernandez, executive vice president and president of manufacturing operations. Either way, the company is presenting them as its standard.

Inspecting every pen more than 70 times produces a large volume of data. If a run's more than 5,000 documented steps were logged on paper or split across disconnected systems, every batch release could become a reconciliation job. According to Ricks, the Lehigh Valley site will add machine learning, AI and digitally integrated systems to that discipline from day one. That suggests the day-one approach has some precedent inside Lilly.

Full automation of the material flow still doesn't mean an empty building. The 850 permanent roles include operations staff and lab technicians, and Ricks said the technology will work for the people running the site, not the reverse. For plant leaders writing their own automation business cases, Lilly's design automates the movement of materials while people stay in charge of the process.

The fourth injectable site in a standard design

Lehigh Valley isn't a one-off design. It is the fourth of Lilly's U.S. injectable and device sites announced since 2020, after Kenosha, Wisconsin, and Concord and Research Triangle Park in North Carolina. In April, Dan VonDielingen, Lilly's senior vice president of global parenteral network expansion, told an INTERPHEX audience that the company standardizes new sites using lessons from its existing plants and its contract manufacturers. He also said it relies on automation and robotics to remove variability.

Lilly's release lays out the full domestic network of 10 sites announced since 2020, part of more than $50 billion in U.S. manufacturing commitments:

• API (five sites): Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two in Lebanon, Indiana, including the Lilly Medicine Foundry for new production methods and clinical trial supply
• Injectable medicines and devices (four sites): Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; Lehigh Valley, Pennsylvania
• Genetic medicines (one site): Lebanon Advanced Therapies in Lebanon, Indiana

Standardization changes the math for suppliers. A filling line, inspection system or warehouse automation package qualified at one of the earlier injectable sites could repeat at Lehigh Valley, and lessons from Kenosha or Concord could become part of the Pennsylvania design before construction gets far. Pharmaceutical Executive reported that Sarah O'Keeffe, a group vice president in Lilly's product research and development organization, has described cutting days off the path to patients as a core goal. Repeating a proven design is one of the most direct ways a manufacturer can do that.

Signals between now and 2031

Lilly is hiring in the Lehigh Valley now, so the pace of hiring for technical roles could show how early the company is building the site's operating team. Governor Josh Shapiro called the project the largest life sciences investment in Pennsylvania's history, WFMZ reported. The site is aiming for LEED Gold certification. Lilly has also committed as much as $1 million across five years to the Community Fund of Upper Macungie Township, supporting a program on healthy living and nutrition, access to fresh food, health resources and community programming.

The clearest test is clinical. Lilly's several Phase 3 clinical trials of retatrutide cover obesity, and overweight in people with at least one weight-related medical problem, as well as cardiovascular outcomes, chronic low back pain, type 2 diabetes, moderate-to-severe obstructive sleep apnea, knee osteoarthritis pain, and metabolic dysfunction-associated steatotic liver disease. Each readout could show how much of the plant's planned output a single molecule might fill. Because Ricks has called it an export site, the plant could also supply markets well beyond Pennsylvania.